Pierre Geborek

Medicine & Life Sciences

1. Rheumatoid Arthritis 100%
2. Tumor Necrosis Factor Inhibitors 36%
3. Sweden 31%
4. Arthritis 26%
5. Infliximab 25%
6. Methotrexate 24%
7. Etanercept 24%
8. Pneumococcal Vaccines 17%
9. Conjugate Vaccines 17%
10. Biological Products 17%
11. Antirheumatic Agents 17%
12. Synovial Fluid 16%
13. Rheumatic Diseases 16%
14. Tumor Necrosis Factor-alpha 15%
15. Therapeutics 13%
16. Vaccination 12%
17. Antibody Formation 11%
18. Psoriatic Arthritis 11%
19. Joints 11%
20. Quality-Adjusted Life Years 10%
21. Cohort Studies 10%
22. Pharmaceutical Preparations 8%
23. Observational Studies 8%
24. Rheumatology 8%
25. Cartilage Oligomeric Matrix Protein 8%
26. Antibodies 7%
27. Registries 7%
28. Rituximab 6%
29. Ankylosing Spondylitis 6%
30. Cost-Benefit Analysis 6%
31. Spondylarthropathies 6%
32. Adalimumab 6%
33. Knee Joint 6%
34. Cytidine Deaminase 5%
35. Health 5%
36. Hand 5%
37. Hydroxychloroquine 5%
38. Costs and Cost Analysis 5%
39. Systemic Scleroderma 5%
40. Sulfasalazine 5%
41. 13-valent pneumococcal vaccine 5%
42. Systemic Vasculitis 5%
43. Cartilage 5%
44. Spondylarthritis 5%
45. Knee 5%